ANRO NYSE Week ended 31 Jul 2026

Weekly Investor Report

Alto Neuroscience, Inc. · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 27.07 USD
1.1% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 24.5% above the Trend Line and sits at 93.1% of its 52-week range. The latest completed week returned 1.1%, after a 9.2% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 55/100 conviction, while the latest news-sentiment score is 60/100. Near-term considerations: price is close to its 52-week high; volume confirmation is below normal; earnings are due in 10d.

Setup score 66 out of 100
Latest Close 27.07 USD 31 Jul 2026
1W Return 1.1% latest completed week
4W Return 9.2% short-term follow-through
12W Return 11.6% quarterly tape
Trend Breadth 94.2% 49 of 52 weeks active
Volume Ratio 0.8x vs 13-week average
What is working
  • The trend backdrop is active with a 49-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • 8 reversal markers appear in the recent smart-money tape.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 1.1% Latest completed week; four-week move 9.2%. Indicator stack 97/63 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 55/100 conviction; expected move 17.6%. News sentiment 60/100 25 relevant articles in the latest sentiment read. Event risk 10d Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 24.5% above the Trend Line and sits at 93.1% of its 52-week range. The latest completed week returned 1.1%, after a 9.2% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.7212-week average 0.77

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure5/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.72Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers88 reversal markers

No recent accumulation markers. 8 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 9.2% over four weeks, 11.6% over 12 weeks, and 787.5% over one year. The current trend has remained active for 49 consecutive weeks.

Performance by holding period

1W1.1%
4W9.2%
12W11.6%
26W74.9%
52W787.5%
Active trend streak49 weeks
Active weeks in one year49
Trend breadth94.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.11Latest activity-pressure read.
Pressure change137.7%Four-week change in activity pressure.
Leadership53.11Latest relative-leadership reading.
RS change-6.2%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 64% Model confidence 61%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength77/100Blend of value, momentum, and quality. Underlying universe rank 24; rank 1 is best.
Value63/100Relative valuation strength. Underlying universe rank 38; rank 1 is best.
Quality62/100Profitability and accounting quality. Underlying universe rank 39; rank 1 is best.
Momentum64/100Medium-term price momentum. Underlying universe rank 37; rank 1 is best.
Growth64/100Revenue and earnings growth. Underlying universe rank 37; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-7.9%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
1/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-16.3%
Net share repurchases relative to market value.
Shareholder yield
-16.3%
Dividend yield plus net buyback yield.
Net debt / EBITDA
3.6x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

ANRO shows volatility options pressure with a 55/100 conviction score, put-call volume ratio of 0.15, expected move of 17.6%, and Sharemaestro trend signal active.

Conviction55/100
Expected move17.6%
Put/call volume0.15
Pressure80
Speculation11
Volatility96
Trend agreement36
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment60/100

Weighted news tone is neutral across 25 relevant articles.

10 positive · 14 neutral · 1 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings10dNext report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
Options expected move17.6%Nearest-chain priced movement where available.
52-week drawdown-6.2%Distance below the 52-week high.
13-week volatility8.9%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher15 of 2611 weeks finished lower.
Best week+21.7%Week of 17 Apr.
Worst week-11.5%Week of 24 Apr.
Latest week+1.1%Week of 31 Jul.

Shape of recent returns

Strong gains13
Modest gains2
Flat weeks0
Modest losses4
Sharp losses7
Recent vol8.9%13-week weekly-return volatility.
Base vol17.9%52-week weekly-return volatility.
Up/down split30/22Count of positive and negative weeks in the 52-week window.
Average skew14.4% / -6.6%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape66/100

Trend, activity pressure, participation, and risk combine to a 66/100 tape read.

 Indicator analysis66/100

Latest 12-week confirmation: trend 12/12, activity pressure 5/12, relative leadership 12/12.

Activity pressure 0.72; 8 reversal markers Factors66/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 89; Small Cap Core rank 45 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options47/100

ANRO shows volatility options pressure with a 55/100 conviction score, put-call volume ratio of 0.15, expected move of 17.6%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 17.6% Sentiment60/100

Weighted news tone is neutral across 25 relevant articles.

Alto Neuroscience, Inc. Revenue Breakdown – NYSE:ANRO Insiders50/100

No recent insider transaction evidence is stored.

 Earnings10d

Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202627.07 USD1.1%21.75 USD11.45 USD0.1153.111.9MOn
24 Jul 202626.78 USD-2.8%21.40 USD11.33 USD0.0157.132.0MOn
17 Jul 202627.54 USD4.0%21.12 USD11.21 USD0.1564.954.5MOn
10 Jul 202626.48 USD6.9%20.87 USD11.08 USD-0.1260.633.3MOn
3 Jul 202624.78 USD-8.4%20.49 USD10.96 USD-0.2956.631.9MOn
26 Jun 202627.04 USD18.9%20.11 USD10.85 USD-0.4379.405.9MOn
19 Jun 202622.74 USD5.9%19.67 USD10.72 USD-0.7652.001.3MOn
12 Jun 202621.47 USD17.6%19.35 USD10.62 USD-0.7148.642.1MOn
5 Jun 202618.26 USD-9.0%19.04 USD10.53 USD-0.4730.341.8MOn
29 May 202620.07 USD-5.4%18.82 USD10.47 USD-0.0342.62985.2KOn
22 May 202621.22 USD-7.7%18.62 USD10.39 USD0.4556.561.8MOn
15 May 202622.98 USD-5.3%18.28 USD10.30 USD0.8475.331.9MOn
8 May 202624.26 USD-2.7%17.72 USD10.19 USD1.1391.031.7MOn
1 May 202624.94 USD1.7%17.10 USD10.07 USD1.11107.721.0MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.